Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA9 | Q16790 | 4/20 | 0.38 |
| ▸ | PREP | P48147 | 3/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | RARA | P10276 | 1/20 | 0.31 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.31 |
| ▸ | RARB | P10826 | 1/20 | 0.31 |
| ▸ | RARG | P13631 | 1/20 | 0.31 |
| ▸ | GOT1 | P17174 | 1/20 | 0.31 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5828207 | 0.77 | RARA (0.35) | CA12CA1CA9LMNAMEN1 | |
| SCHEMBL3313281 | 0.77 | HDAC11 (0.32) | CNR2LMNAMEN1KMT2ANR1I2 | |
| SCHEMBL404791 | 0.76 | HDAC11 (0.36) | LMNAMEN1KMT2ANR1I2PGR | |
| SCHEMBL3892539 | 0.75 | RARB (0.59) | CA12CA1CA9LMNAMEN1 | |
| SCHEMBL8660077 | 0.74 | RARA (0.38) | CA12CA1CA9LMNAMEN1 | |
| SCHEMBL13330393 | 0.73 | HTT (0.35) | CNR2MEN1KMT2AALDH1A1 | |
| SCHEMBL8796347 | 0.73 | RARA (0.31) | LMNAMEN1KMT2ANR1I2PGR | |
| SCHEMBL22128458 | 0.71 | CA12 (0.46) | CA12CA1CA9PREP | |
| SCHEMBL23212248 | 0.70 | CA12 (0.34) | CA12CA1CA9PREPPOLB | |
| SCHEMBL8398381 | 0.70 | RARB (0.37) | LMNAMEN1KMT2ANR1I2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113816-A1 | METHOD FOR PREPARTION OF SUBSTITUTED ADAMANTYLARYMAGNESIUM HALIDES | JSC GRINDEKS (LV) | 2010-05-06 | — | — | US | disclosed |
| EP-2129679-A2 | A METHOD FOR PREPARATION OF SUBSTITUTED ADAMANTYLARYLMAGNESIUM HALIDES | Grindeks, a joint stock company (LV) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008080993-A2 | A METHOD FOR PREPARATION OF SUBSTITUTED ADAMANTYLARYLMAGNESIUM HALIDES | KALVINSH IVARS (LV) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113816-A1 | METHOD FOR PREPARTION OF SUBSTITUTED ADAMANTYLARYMAGNESIUM HALIDES | AGL, MACROD1, MACROD2 | CA12 1439/4885CA1 527/4885CA9 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.